Finishing breast cancer treatment can bring a great sense of relief. But for many women with hormone receptor positive breast cancer, treatment does not end with surgery, chemotherapy or radiation. Hormone therapy, also called endocrine therapy, may continue for several years to reduce the risk of the cancer returning.
This often leads to an important question: When is it safe to stop hormone therapy after breast cancer?
The answer is not the same for everyone.
Why is hormone therapy continued after breast cancer?
Hormone receptor positive breast cancer can use hormones such as oestrogen or progesterone to grow. Medicines such as tamoxifen and aromatase inhibitors work by blocking the effect of these hormones or reducing their production.
For women with hormone receptor positive breast cancer, at least five years of endocrine therapy is commonly recommended after initial treatment. Research shows that taking endocrine therapy for five years or longer can substantially reduce the risk of recurrence and new breast cancers.
However, completing five years does not automatically mean that every woman should stop treatment.
Is five years enough?
For some women, yes. For others, continuing treatment for up to 7 to 10 years may provide additional protection against recurrence.
The decision depends on the person's individual risk of late recurrence. Doctors consider factors such as the original tumour size, lymph node involvement, tumour biology, menopausal status and the treatment already received.
The risk of breast cancer recurrence can continue for many years after the initial diagnosis, particularly in hormone receptor positive disease. This is why the five year mark is often a point for reassessment rather than an automatic stopping point.
Some women may therefore benefit from extended endocrine therapy, while for others the additional benefit may be relatively small.
What if the side effects are difficult to manage?
Hormone therapy can cause side effects such as hot flashes, night sweats, joint or muscle discomfort, vaginal dryness, changes in sexual health and menstrual changes. Aromatase inhibitors can also affect bone health.
If side effects are making treatment difficult, stopping the medicine on your own is usually not the best solution.
There may be other options. Depending on the medicine and individual situation, your oncologist may consider changing the drug, switching between tamoxifen and an aromatase inhibitor, or managing specific side effects.
The goal is to find a treatment plan that provides meaningful protection while remaining manageable in everyday life.
Can hormone therapy ever be stopped earlier?
There are situations where treatment may need to be interrupted or changed. For example, a woman may have significant side effects, other medical concerns or personal circumstances that require a discussion about changing treatment.
Fertility and pregnancy can also influence treatment decisions in younger women. Research from the POSITIVE trial found that selected women with early stage hormone receptor positive breast cancer could temporarily pause endocrine therapy to attempt pregnancy, under medical supervision, without an apparent increase in short term recurrence risk.
Treatment was then planned to continue so that the intended overall duration could still be achieved.
This is very different from permanently stopping treatment and should always be planned with the treating oncology team.
What about menopausal hormone replacement therapy?
There is an important distinction between endocrine therapy for breast cancer and hormone replacement therapy for menopausal symptoms.
A breast cancer survivor should not assume that completing five years of tamoxifen or an aromatase inhibitor means that menopausal hormone replacement therapy is automatically safe.
Systemic menopausal hormone replacement therapy is generally avoided after breast cancer, particularly after hormone receptor positive disease, because of concerns about stimulating hormone sensitive cancer cells. ASCO specifically notes that recent changes to HRT warnings for people without cancer do not apply to women with a history of estrogen responsive cancers.
If menopausal symptoms are affecting quality of life, discuss non hormonal options and appropriate local treatments with your oncologist.
Dr. Pragati Singhal
